Dupixent (dupilumab) - Sanofi, Regeneron
Twelve-Month Real-World Outcomes With Dupilumab In Hispanic And Non-Hispanic Patients With Asthma: Results From RAPID (ACAAI 2026) - Oct 28, 2026 - Abstract #R137; Pres time: Nov 13, 2026; 04:20 PM - 06:00 PM; Location: Phoenix Convention Center • North Halls 4–6 (Lower Level); Monitor 19; No abstract available 
Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases
https://annualmeeting.acaai.org/2026/submit_abstract.cfm
 
Oct 28, 2026
 
Prev Next